LABORATORY


What sets us apart: the Molecular Oncology and Pathology Laboratory
The Pangaea Oncology laboratory, which serves IOR, is located in the Quirón Dexeus University Hospital, Barcelona. Its primary mission is to achieve personalized treatments according to the genetic characteristics of the disease, ensuring the quality, speed and accuracy of results so that therapy can be tailored to each patient.

Each tumor has its own genetic signature. The laboratory offers the possibility of specific molecular diagnosis, with the latest technology in the field of molecular biology, such as the determination of changes in the DNA sequence or the expression of critical genes in cancer using highly sensitive techniques such as PCR, in real-time, massive sequencing (NGS) and gene hybridization and digital counting of the relative abundance of mRNA transcripts.

The laboratory team includes technical staff, biologists, pathologists and highly qualified and specialized investigators who combine experience in Molecular Diagnostics Services, pre-clinical oncology research, R+D Diagnostics, R+D Biomarker Discovery.

Pangaea Oncology is ENAC accredited for genetic analyses in tumor tissue and liquid biopsy samples
Pangaea Oncology was the first pharmacogenomics laboratory in Spain to be accredited, by the National Accreditation Body (ENAC), ISO 15189 Accreditation nº750 / LE15156 toperform genetic testing for cancer patients in liquid biopsy (serum/plasma) samples and tissue samples.In 2020 we got a new accredited tests such as in NGS into Liquid Biopsy (first laboratory in Spain) and Tissue by using QIAGEN Clinical Insight (QCI) , and detection of rearrangementsof the ALK, RET and ROS1 by gene hybridization and digital count of the relative abundance of mRNA transcripts by using N-COUNTER (NANOSTRING).

Accreditation Scope
 


Pangaea participates in several External Quality Assesment (EQA) programs such as:
The laboratory has also been positively audited by the Food and Drug Administration (FDA) as part of regulatory approval for Roche Diagnostics' Cobas® EGFR Mutation Test for non-small-cell lung cancer patients.